
Vertex Pharmaceuticals shares rise 17% in 2027 on strong Q3 sales and institutional buying.
Vertex Pharmaceuticals reported a 12% year-over-year revenue increase to $3.44 billion in Q3 2027, driven by cystic fibrosis and new products. Despite a slight dip in non-GAAP earnings per share, the company raised its full-year revenue guidance to $...

